The Global Transcatheter Mitral And Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market was valued at USD 2.5 billion in 2025 and is estimated to grow at a CAGR of 10.7% to reach USD 6.8 billion by 2035.
The market growth reflects the rising adoption of minimally invasive structural heart procedures for patients who are considered high risk or unsuitable for traditional open-heart surgery. Increasing cases of mitral and tricuspid valve disorders, supported by the expanding elderly population and the growing prevalence of cardiovascular conditions, are creating sustained demand for advanced transcatheter treatment options. Healthcare providers are increasingly adopting catheter-based approaches because they offer benefits such as reduced recovery periods, lower procedural burden, and improved treatment accessibility for complex patient groups. The expansion of specialized structural heart programs and improved hospital capabilities are further supporting the adoption of TMVR and TTVR procedures. As clinical experience continues to increase and long-term outcomes become more established, the use of transcatheter valve technologies is gradually expanding beyond high-risk patients toward broader patient populations. Growing investments in innovative valve repair and replacement technologies, along with advancements in imaging, procedural techniques, and device design, are expected to strengthen market growth. The latest market projections are based on findings from the report published by Global Market Insights Inc.
The repair devices segment held 83% share in 2025 and is expected to grow at a CAGR of 10.5% through 2035. The strong position of repair devices is supported by their established clinical adoption, wider patient eligibility, and extensive evidence supporting their use in structural heart disease treatment. These devices benefit from broader reimbursement acceptance, longer commercial availability, and greater integration into treatment strategies for valve disorders. Continued clinical advancements and increasing physician familiarity are expected to maintain the segment’s dominance throughout the forecast period.
The hospitals segment held 88% share in 2025 and is projected to grow at a CAGR of 10.4% through 2035. The complexity of transcatheter structural heart procedures requires advanced hospital infrastructure, specialized cardiac facilities, and coordinated multidisciplinary expertise. Hospitals continue to serve as the preferred location for these interventions due to their ability to provide comprehensive procedural support, advanced imaging capabilities, and specialized cardiovascular care teams. The continued development of structural heart programs at healthcare institutions is expected to support further market expansion.
North America Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market held 40.2% share in 2025 and projected to grow at a CAGR of 10.5% through 2035. The United States contributes most of the regional market revenue due to strong healthcare infrastructure, established structural heart programs, and favorable reimbursement conditions for transcatheter valve procedures. Increasing adoption of advanced cardiac technologies, growing investment in specialized treatment centers, and expanding clinical acceptance of transcatheter interventions are supporting regional growth. Continued regulatory advancements and broader availability of reimbursement pathways are expected to further accelerate the adoption of transcatheter mitral and tricuspid valve repair and replacement technologies across North America.
Major companies operating in the Global Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market include Abbott Laboratories, Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic, LivaNova PLC, Venus Medtech, Neovasc Inc., Jenscare, TRiCares GmbH, Cardiovalve Ltd., Polares Medical, and Highlife SAS. Companies operating in the Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market are strengthening their market position through continuous innovation, product development, strategic collaborations, and expansion of clinical capabilities. Industry participants are investing in advanced valve technologies, improved delivery systems, and enhanced procedural solutions to address growing demand for minimally invasive cardiac treatments. Companies are also focusing on clinical research, regulatory approvals, and partnerships with healthcare providers to increase adoption and expand patient access. Expanding product portfolios, strengthening physician training programs, and improving device performance remain important strategies for gaining competitive advantage.
This product will be delivered within 2-4 business days.
The market growth reflects the rising adoption of minimally invasive structural heart procedures for patients who are considered high risk or unsuitable for traditional open-heart surgery. Increasing cases of mitral and tricuspid valve disorders, supported by the expanding elderly population and the growing prevalence of cardiovascular conditions, are creating sustained demand for advanced transcatheter treatment options. Healthcare providers are increasingly adopting catheter-based approaches because they offer benefits such as reduced recovery periods, lower procedural burden, and improved treatment accessibility for complex patient groups. The expansion of specialized structural heart programs and improved hospital capabilities are further supporting the adoption of TMVR and TTVR procedures. As clinical experience continues to increase and long-term outcomes become more established, the use of transcatheter valve technologies is gradually expanding beyond high-risk patients toward broader patient populations. Growing investments in innovative valve repair and replacement technologies, along with advancements in imaging, procedural techniques, and device design, are expected to strengthen market growth. The latest market projections are based on findings from the report published by Global Market Insights Inc.
The repair devices segment held 83% share in 2025 and is expected to grow at a CAGR of 10.5% through 2035. The strong position of repair devices is supported by their established clinical adoption, wider patient eligibility, and extensive evidence supporting their use in structural heart disease treatment. These devices benefit from broader reimbursement acceptance, longer commercial availability, and greater integration into treatment strategies for valve disorders. Continued clinical advancements and increasing physician familiarity are expected to maintain the segment’s dominance throughout the forecast period.
The hospitals segment held 88% share in 2025 and is projected to grow at a CAGR of 10.4% through 2035. The complexity of transcatheter structural heart procedures requires advanced hospital infrastructure, specialized cardiac facilities, and coordinated multidisciplinary expertise. Hospitals continue to serve as the preferred location for these interventions due to their ability to provide comprehensive procedural support, advanced imaging capabilities, and specialized cardiovascular care teams. The continued development of structural heart programs at healthcare institutions is expected to support further market expansion.
North America Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market held 40.2% share in 2025 and projected to grow at a CAGR of 10.5% through 2035. The United States contributes most of the regional market revenue due to strong healthcare infrastructure, established structural heart programs, and favorable reimbursement conditions for transcatheter valve procedures. Increasing adoption of advanced cardiac technologies, growing investment in specialized treatment centers, and expanding clinical acceptance of transcatheter interventions are supporting regional growth. Continued regulatory advancements and broader availability of reimbursement pathways are expected to further accelerate the adoption of transcatheter mitral and tricuspid valve repair and replacement technologies across North America.
Major companies operating in the Global Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market include Abbott Laboratories, Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic, LivaNova PLC, Venus Medtech, Neovasc Inc., Jenscare, TRiCares GmbH, Cardiovalve Ltd., Polares Medical, and Highlife SAS. Companies operating in the Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market are strengthening their market position through continuous innovation, product development, strategic collaborations, and expansion of clinical capabilities. Industry participants are investing in advanced valve technologies, improved delivery systems, and enhanced procedural solutions to address growing demand for minimally invasive cardiac treatments. Companies are also focusing on clinical research, regulatory approvals, and partnerships with healthcare providers to increase adoption and expand patient access. Expanding product portfolios, strengthening physician training programs, and improving device performance remain important strategies for gaining competitive advantage.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Device Type, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Indication, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by End Use, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 9 Company Profiles
Companies Mentioned
- Abbott Laboratories
- Edwards Lifesciences Corporation
- Boston Scientific Corporation
- Medtronic
- LivaNova PLC
- Venus Medtech
- Neovasc Inc.
- Jenscare
- TRiCares GmbH
- Cardiovalve Ltd.
- Polares Medical
- Highlife SAS
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 130 |
| Published | July 2026 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 2.5 Billion |
| Forecasted Market Value ( USD | $ 6.8 Billion |
| Compound Annual Growth Rate | 10.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
